ViRexx announces new CFO

 In Uncategorized

ViRexx Medical Corp. (TSX:VIR) (AMEX:REX) a company focused on immunotherapy treatments for certain cancers, chronic hepatitis B & C and embolotherapy treatments for tumors, has announced the appointment of Scott M. Langille as Chief Financial Officer effective May 2, 2006.

Mr. Langille joins ViRexx with an extensive list of professional accomplishments. As Senior V.P. & Chief Financial Officer with Henry Schein Ash Arcona, he was responsible for all facets of financial management and company stewardship in financial and product accounting, business planning and logistics. Previously, Mr. Langille held the position of Chief Financial Officer at 401 Capital Partners Inc., where he led the company in activities related to a Pre-Initial Public Offering (IPO). Leading up to his position at ViRexx, Mr. Langille also held progressive management positions in the areas of in-licensing and out-licensing, capital financing, acquisitions and strategic planning with leading pharmaceutical companies including privately held Verum Pharmaceuticals Inc., Biovail Corporation, Altimed Pharmaceutical Company, and Syntex Inc.

About ViRexx Medical Corp.

ViRexx is an Edmonton, Alberta based biotechnology company focused on the development of novel therapeutic products for the treatment of certain cancers and specified chronic viral infections. ViRexx’s most advanced programs include drug candidates for the treatment of ovarian cancer, chronic hepatitis B and C and solid tumors.

Contact Us

Send us an email and we'll get back to you, asap.

Start typing and press Enter to search